Medicinal Chemistry, Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan.
J Med Chem. 2012 Jun 14;55(11):5255-69. doi: 10.1021/jm300259r. Epub 2012 May 31.
Design, synthesis, and structure-activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF(1)) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.
本文描述了一系列 3-二烷基氨基-7-苯基吡唑并[1,5-a]吡啶(I)作为促肾上腺皮质激素释放因子 1(CRF1)受体选择性拮抗剂的设计、合成和构效关系。从这项工作中脱颖而出的最突出的化合物是 46(E2508),它具有很强的体外活性、优良的药物样特性和在应激相关疾病动物模型中的良好口服疗效。它已进入临床试验。